查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1973859

標靶蛋白分解市場分析及預測（至2035年）：依類型、產品類型、服務、技術、應用、最終用戶、製程、模式、階段分類

Targeted Protein Degradation Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Mode, Stage
出版日期: | 出版商: Global Insight Services | 英文 346 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

標靶蛋白分解市場預計將從2024年的6億美元成長到2034年的95億美元，複合年成長率約為31.8%。該市場涵蓋旨在選擇性分解致病蛋白的創新治療方法，提供了一種超越傳統抑制的新方法。此市場利用蛋白水解靶向嵌合體（PROTACs）和分子黏合劑，實現精準的治療性介入。在腫瘤學和神經退化性疾病領域日益成長的關注、藥物研發技術的進步以及領先製藥公司之間戰略聯盟的推動下，該市場正穩步成長。

由於藥物研發技術和個人化醫療的進步，標靶蛋白分解市場預計將迎來顯著成長。小分子分解劑在性能方面主導，這主要歸功於它們能夠靶向過去被認為「不可成藥」的蛋白質。異雙功能分解劑是小分子分解劑的一個子類，因其更高的特異性和療效而備受關注。 PROTAC（蛋白水解靶向嵌合體）子類在性能方面位居第二，這反映了其在多種疾病領域展現出的巨大治療潛力和廣泛的應用前景。同時，在治療領域方面，腫瘤學由於對新型癌症治療方法的迫切需求而佔據主導地位。神經病學緊隨其後，這主要得益於神經退化性疾病研究的不斷深入。人們對標靶治療的日益關注正在推動製藥公司和研究機構之間的合作，從而加速創新。人工智慧在藥物研發過程中的應用，透過最佳化標靶識別和強化藥物研發管線，進一步促進了市場擴張。

市場區隔
類型 小分子化合物、生物製劑、PROTAC、分子黏合劑、去甲醯亞胺、E3連接酶調變器、Chaperone介導的分解劑
產品 治療藥物、研究工具和診斷
服務 客製化合成、藥物發現服務、分析服務、諮詢服務
科技 泛素-蛋白酶體系統、自噬-溶小體途徑、內質網相關蛋白分解
應用領域 腫瘤科、神經科、感染疾病、心血管疾病科、免疫科、代謝疾病科、眼科
最終用戶 製藥公司、生技公司、學術研究機構、受託研究機構
過程 藥物發現、臨床前開發、臨床試驗、監管核准、商業化及上市後監測
給藥途徑 口服、靜脈注射、皮下注射、局部
步 臨床前、I期、II期、III期、已通過核准

市場概況：

標靶蛋白分解（TPD）市場正經歷動態變化，主要產業領導者佔據了顯著的市場佔有率。受新型療法的推出和藥物研發進展的推動，定價策略競爭仍然激烈。近期，一些公司推出新產品，旨在滿足未被滿足的醫療需求並提高治療效果，這進一步推動了市場發展。對個人化醫療和標靶治療的關注持續推動著創新，為該領域的持續成長奠定了基礎。標靶蛋白分解市場的競爭異常激烈，主要參與者透過策略聯盟和併購來爭奪主導。監管因素，尤其是在美國和歐洲，對塑造市場動態起著至關重要的作用。這些法規確保了藥物的安全性和有效性，並影響產品核可和市場准入的速度。對競爭對手的比較分析表明，他們高度重視研發，並致力於利用最尖端科技。生物技術的進步和研發投入的不斷增加正在推動市場的進一步擴張，為市場前景提供了良好的基礎。

主要趨勢和促進因素：

標靶蛋白分解市場正經歷快速成長，這主要得益於幾個關鍵趨勢和促進因素。生物技術和製藥研發投入的不斷增加是關鍵促進因素，因為越來越多的公司正在尋求針對複雜疾病的創新治療方法。蛋白質體學和生物資訊學的進步也支持了這一趨勢，它們正在加深我們對蛋白質相互作用和分解途徑的理解。精準醫療的日益普及也推動了市場擴張，因為標靶蛋白分解能夠提供更具特異性、副作用更少的治療方案。學術機構和產業界的合作正在加速新型分解技術的發展。小分子分解劑（例如PROTAC和分子黏合劑）的興起是一大趨勢，它們為靶向以前被認為「無法治療」的蛋白質提供了新的機制。此外，監管機構的支持以及突破性治療方法的加速核准流程也在刺激該市場的創新。擁有強大研發管線和策略夥伴關係關係投資的公司能夠更好地掌握這些新機遇，推動未來的成長並鞏固市場領導地位。

限制與挑戰：

標靶蛋白分解市場面臨許多顯著的限制與挑戰。其中一個關鍵挑戰是研發過程的複雜性，這會導致研發週期延長和成本增加。這種複雜性會抑制投資，減緩創新步伐。監管障礙也是一大阻礙，因為不斷變化的環境要求企業遵守嚴格的指導方針，這可能會延遲市場准入。此外，目前缺乏評估標靶蛋白分解劑療效和安全性的標準化通訊協定。這種缺失使臨床試驗設計複雜化，並阻礙了建立可靠的成功標準。智慧財產權問題進一步加劇了市場挑戰，專利糾紛會扼殺競爭和創新。最後，該領域專業人才短缺。人才短缺限制了研發能力，阻礙了市場的整體成長和發展。所有這些因素共同限制了標靶蛋白分解市場的潛力。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 低分子化合物
    • 生物製劑
    • PROTACs
    • 分子黏合劑
    • 地塞米胺
    • E3連接酶調變器
    • Chaperone介導的分解劑
  • 市場規模及預測：依產品分類
    • 治療藥物
    • 研究工具
    • 診斷試劑
  • 市場規模及預測：依服務分類
    • 客製合成
    • 藥物發現服務
    • 分析服務
    • 諮詢服務
  • 市場規模及預測：依技術分類
    • 泛素-蛋白酶體系統
    • 自噬-溶小體途徑
    • 內質網相關蛋白分解
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 神經病學
    • 感染疾病
    • 心血管疾病
    • 免疫學
    • 代謝性疾病
    • 眼科學領域
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 生技公司
    • 學術和研究機構
    • 合約研究機構
  • 市場規模及預測：依製程分類
    • 藥物發現
    • 臨床前開發
    • 臨床試驗
    • 監管部門核准
    • 商業化
    • 上市後監測
  • 市場規模及預測：依作用機制分類
    • 口服
    • 靜脈注射
    • 皮下注射
    • 主題
  • 市場規模及預測：依發展階段分類
    • 臨床前階段
    • 第一階段
    • II 期研究
    • III期臨床試驗
    • 已通過核准的

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Arvinas
  • Nurix Therapeutics
  • Kymera Therapeutics
  • C4 Therapeutics
  • Foghorn Therapeutics
  • Vividion Therapeutics
  • Monte Rosa Therapeutics
  • Cullgen
  • Dialectic Therapeutics
  • Mission Therapeutics
  • Progenra
  • Cedilla Therapeutics
  • Kymera Therapeutics
  • Bicycle Therapeutics
  • Forma Therapeutics

第9章：關於我們

簡介目錄
Product Code: GIS34327

Targeted Protein Degradation Market is anticipated to expand from $0.6 billion in 2024 to $9.5 billion by 2034, growing at a CAGR of approximately 31.8%. The Targeted Protein Degradation Market encompasses innovative therapies designed to selectively degrade disease-causing proteins, offering a novel approach beyond traditional inhibition. This market leverages proteolysis-targeting chimeras (PROTACs) and molecular glues, facilitating precise therapeutic interventions. With rising interest in oncology and neurodegenerative disorders, the market is poised for growth, driven by advancements in drug discovery technologies and strategic collaborations among pharmaceutical giants.

The Targeted Protein Degradation Market is poised for significant growth, driven by advancements in drug discovery and personalized medicine. The small molecule degraders segment leads in performance, primarily due to their ability to target previously 'undruggable' proteins. Heterobifunctional degraders, a sub-segment within small molecule degraders, are gaining traction, offering enhanced specificity and efficacy. The PROTACs (Proteolysis Targeting Chimeras) sub-segment is the second highest performing, reflecting its promising therapeutic potential and versatility across various disease areas. Meanwhile, the therapeutic area segment is dominated by oncology applications, given the urgent need for novel cancer treatments. Neurological disorders follow closely, driven by increasing research into neurodegenerative diseases. The burgeoning interest in targeted therapies is fostering collaboration between pharmaceutical companies and research institutions, accelerating innovation. The integration of artificial intelligence in drug discovery processes further supports market expansion, optimizing target identification and enhancing drug development pipelines.

Market Segmentation
TypeSmall Molecules, Biologics, PROTACs, Molecular Glues, Degronimids, E3 Ligase Modulators, Chaperone-Mediated Degraders
ProductTherapeutic Agents, Research Tools, Diagnostic Agents
ServicesCustom Synthesis, Drug Discovery Services, Analytical Services, Consulting Services
TechnologyUbiquitin-Proteasome System, Autophagy-Lysosome Pathway, Endoplasmic Reticulum-Associated Protein Degradation
ApplicationOncology, Neurology, Infectious Diseases, Cardiovascular Diseases, Immunology, Metabolic Disorders, Ophthalmology
End UserPharmaceutical Companies, Biotechnology Companies, Academic and Research Institutions, Contract Research Organizations
ProcessDiscovery, Preclinical Development, Clinical Trials, Regulatory Approval, Commercialization, Post-Market Surveillance
ModeOral, Intravenous, Subcutaneous, Topical
StagePreclinical, Phase I, Phase II, Phase III, Approved

Market Snapshot:

The Targeted Protein Degradation Market is experiencing a dynamic shift with significant market share held by key industry leaders. Pricing strategies remain competitive, influenced by the introduction of novel therapeutics and advancements in drug discovery. Recent product launches have invigorated the market, as companies strive to address unmet medical needs and enhance therapeutic efficacy. The focus on personalized medicine and targeted therapies continues to drive innovation, setting the stage for sustained growth in this sector. Competition within the Targeted Protein Degradation Market is intense, with major players vying for dominance through strategic partnerships and mergers. Regulatory influences, particularly in the United States and Europe, play a crucial role in shaping market dynamics. These regulations ensure safety and efficacy, impacting the pace of product approvals and market entry. Benchmarking against competitors reveals an emphasis on research and development, aiming to leverage cutting-edge technologies. The market's trajectory is promising, with advancements in biotechnology and increased investment in R&D fueling further expansion.

Geographical Overview:

The Targeted Protein Degradation (TPD) market is witnessing robust growth across diverse regions, each demonstrating unique potential. North America leads the charge, propelled by cutting-edge research and substantial investments in biotechnology. The region's focus on innovative drug discovery and development further bolsters this market, positioning it as a growth leader. In Europe, the TPD market is gaining momentum, driven by strong governmental support and a well-established pharmaceutical industry. The region's emphasis on precision medicine and advanced therapeutic solutions enhances its market prospects. Meanwhile, Asia Pacific is emerging as a significant growth pocket, fueled by rapid technological advancements and increasing investments in healthcare R&D. Countries like China and Japan are at the forefront, spearheading initiatives in targeted therapies. Latin America and the Middle East & Africa are nascent markets with burgeoning potential. These regions are increasingly recognizing the importance of TPD in addressing unmet medical needs and advancing therapeutic innovation.

Key Trends and Drivers:

The Targeted Protein Degradation Market is experiencing rapid growth, driven by several key trends and drivers. Increasing investment in biotechnology and pharmaceutical research is a primary driver, as companies seek innovative therapies for complex diseases. This trend is supported by advancements in proteomics and bioinformatics, which enhance the understanding of protein interactions and degradation pathways. A growing focus on precision medicine is also fueling market expansion, as targeted protein degradation offers more specific treatment options with potentially fewer side effects. Collaborations between academic institutions and industry players are accelerating the development of novel degradation technologies. The rise of small molecule degraders, such as PROTACs and molecular glues, is a significant trend, offering new mechanisms to target previously 'undruggable' proteins. Furthermore, regulatory support and expedited approval processes for breakthrough therapies are encouraging innovation in this market. Companies investing in robust pipelines and strategic partnerships are well-positioned to capitalize on these emerging opportunities, driving future growth and market leadership.

Restraints and Challenges:

The targeted protein degradation market encounters several notable restraints and challenges. A primary challenge is the complexity of drug development processes, which can result in extended timelines and increased costs. This complexity often deters investment and slows the pace of innovation. Regulatory hurdles also pose significant obstacles, as the evolving landscape requires compliance with stringent guidelines that can delay market entry. Additionally, there is a lack of standardized protocols for evaluating the efficacy and safety of targeted protein degraders. This absence complicates clinical trial designs and hinders the establishment of robust benchmarks for success. Intellectual property issues further exacerbate market challenges, with patent conflicts potentially stifling competition and innovation. Lastly, the market faces a scarcity of skilled professionals with expertise in this niche domain. This talent gap limits the capacity for research and development, impeding overall market growth and advancement. These factors collectively restrain the potential of the targeted protein degradation market.

Key Players:

Arvinas, Nurix Therapeutics, Kymera Therapeutics, C4 Therapeutics, Foghorn Therapeutics, Vividion Therapeutics, Monte Rosa Therapeutics, Cullgen, Dialectic Therapeutics, Mission Therapeutics, Progenra, Cedilla Therapeutics, Kymera Therapeutics, Bicycle Therapeutics, Forma Therapeutics

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Mode
  • 2.9 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Small Molecules
    • 4.1.2 Biologics
    • 4.1.3 PROTACs
    • 4.1.4 Molecular Glues
    • 4.1.5 Degronimids
    • 4.1.6 E3 Ligase Modulators
    • 4.1.7 Chaperone-Mediated Degraders
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Therapeutic Agents
    • 4.2.2 Research Tools
    • 4.2.3 Diagnostic Agents
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Custom Synthesis
    • 4.3.2 Drug Discovery Services
    • 4.3.3 Analytical Services
    • 4.3.4 Consulting Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Ubiquitin-Proteasome System
    • 4.4.2 Autophagy-Lysosome Pathway
    • 4.4.3 Endoplasmic Reticulum-Associated Protein Degradation
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Neurology
    • 4.5.3 Infectious Diseases
    • 4.5.4 Cardiovascular Diseases
    • 4.5.5 Immunology
    • 4.5.6 Metabolic Disorders
    • 4.5.7 Ophthalmology
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Pharmaceutical Companies
    • 4.6.2 Biotechnology Companies
    • 4.6.3 Academic and Research Institutions
    • 4.6.4 Contract Research Organizations
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Discovery
    • 4.7.2 Preclinical Development
    • 4.7.3 Clinical Trials
    • 4.7.4 Regulatory Approval
    • 4.7.5 Commercialization
    • 4.7.6 Post-Market Surveillance
  • 4.8 Market Size & Forecast by Mode (2020-2035)
    • 4.8.1 Oral
    • 4.8.2 Intravenous
    • 4.8.3 Subcutaneous
    • 4.8.4 Topical
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Preclinical
    • 4.9.2 Phase I
    • 4.9.3 Phase II
    • 4.9.4 Phase III
    • 4.9.5 Approved

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Mode
      • 5.2.1.9 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Mode
      • 5.2.2.9 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Mode
      • 5.2.3.9 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Mode
      • 5.3.1.9 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Mode
      • 5.3.2.9 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Mode
      • 5.3.3.9 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Mode
      • 5.4.1.9 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Mode
      • 5.4.2.9 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Mode
      • 5.4.3.9 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Mode
      • 5.4.4.9 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Mode
      • 5.4.5.9 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Mode
      • 5.4.6.9 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Mode
      • 5.4.7.9 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Mode
      • 5.5.1.9 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Mode
      • 5.5.2.9 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Mode
      • 5.5.3.9 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Mode
      • 5.5.4.9 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Mode
      • 5.5.5.9 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Mode
      • 5.5.6.9 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Mode
      • 5.6.1.9 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Mode
      • 5.6.2.9 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Mode
      • 5.6.3.9 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Mode
      • 5.6.4.9 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Mode
      • 5.6.5.9 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Arvinas
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Nurix Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Kymera Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 C4 Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Foghorn Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Vividion Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Monte Rosa Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Cullgen
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Dialectic Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Mission Therapeutics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Progenra
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Cedilla Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Kymera Therapeutics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Bicycle Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Forma Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us